MaxCyte Inc - Company Profile
Powered by 
All the sales intelligence you need on MaxCyte Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MaxCyte Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MaxCyte Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MaxCyte Inc (MaxCyte) is a commercial cell engineering company. It provides platform technologies to advance the discovery, development, and commercialization of cell therapeutics. Its proprietary Flow Electroporation technology is utilized by biopharmaceutical companies for the engineering of various cells. MaxCyte's major products include the ExPERT platform, a suite of instruments designed to address the cell therapy market, and an array of proprietary related disposables and consumables. The company serves commercial cell therapy drug and biologic developers, biopharmaceutical companies, and academic and government research institutions. Its products are used in various applications, such as cell and gene therapy, drug discovery, gene editing, and biomanufacturing. It partners with Allogene Therapeutics, Be Biopharma, Beam Therapeutics, and Caribou Biosciences, among others. MaxCyte is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
9713 Key West Avenue, Suite 400, Rockville, Maryland, 20850
Website
www.maxcyte.com
Telephone
1 301 5175556
No of Employees
91
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MXCT (NASD)
Revenue (2024)
$33.0M
-14.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-8.7%
(2024 vs 2023)
Market Cap*
$147.5M
Net Profit Margin (2024)
XYZ
-27.1%
(2024 vs 2023)
* As of and is in US$
MaxCyte Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Consumables: | Processing Assemblies | MaxCyte |
| GMP PAs | Transfection Insourcing Services | MaxCyte GTx |
| RUO Pas | MaxCyte STx | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In February, the company signed a strategic platform license with TG Therapeutics to advance its autoimmune cell therapeutics programs. |
| 2025 | Acquisitions/Mergers/Takeovers | In January, the company acquired SeQure Dx, a provider of on-target and off-target editing assessment services for cell and gene therapies. |
| 2024 | Contracts/Agreements | In September, the company signed strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases. |
Competitor Comparison
| Key Parameters | MaxCyte Inc | Thermo Fisher Scientific Inc | Lonza Group Ltd | Bio-Rad Laboratories Inc | Miltenyi Biotec BV & Co KG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | Germany |
| City | Rockville | Waltham | Basel | Hercules | Bergisch Gladbach |
| State/Province | Maryland | Massachusetts | Basel-Stadt | California | Nordrhein-Westfalen |
| No. of Employees | 91 | 125,000 | 16,866 | 7,450 | 4,700 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Maher Issa Masoud | Chief Executive Officer; Director; President | Executive Board | 2024 | 50 |
| Parmeet Ahuja | Chief Financial Officer | Senior Management | 2026 | - |
| Douglas Swirsky | Chief Financial Officer | Senior Management | - | 55 |
| Ali Soleymannezhad | Chief Commercial Officer | Senior Management | 2024 | - |
| Richard Douglas, Ph.D | Chairman | Non Executive Board | 2021 | 72 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer